Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

South China Morning Post - Nov 3, 2026

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...

Read full article
MORE NEWS
Copyright © 2015 - 2026 Gempak Media. All Rights Reserved.

Subscribe Now!

About Us

Gempak Media delivers the most talked and gempak stories on the Internet to you. Be the first to know about the latest news and don’t forget to share it around.